⌕
Krystal Biotech · KRYS · Nasdaq
Tenet 66 · Solid
Compare
$298.55+0.22%At closeTenet 66 · Solid
$298.55+0.65 (+0.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Krystal Biotech (KRYS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KRYS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 17, 2026 · 17:38 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal Biotech” or the “Company”) (NASDAQ: KRYS).  Such investors are advised to contac…

KRYS +0.2% todayRead at source ↗
● Defense WorldNov 11, 2026 · 01:15 ET
Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey

Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on th…

KRYS +0.2% todayRead at source ↗
● Defense WorldNov 7, 2026 · 06:01 ET
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst ha…

KRYS +0.2% todayRead at source ↗
● BenzingaNov 2, 2026 · 13:43 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech Analyst Says Stock Weakness 'Overblown'

Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.…

KRYS +0.2% todayRead at source ↗
● Seeking AlphaNov 2, 2026 · 13:28 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript…

KRYS +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 12:20 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.…

KRYS +0.2% todayRead at source ↗
● MarketBeatNov 2, 2026 · 11:14 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech Q3 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining updated timelines for sev…

KRYS +0.2% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results

$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell car…

KRYS +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 16
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

KRYS +0.2% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the op…

KRYS +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 12:20 ETEARNINGS EXPECTED BY FEB 16
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.…

KRYS +0.2% todayRead at source ↗
● GlobeNewsWireOct 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscop…

KRYS +0.2% todayRead at source ↗
● Defense WorldOct 13, 2026 · 07:24 ETEARNINGS EXPECTED BY FEB 16
2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC

Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…

KRYS +0.2% todayRead at source ↗
● Seeking AlphaOct 10, 2026 · 06:33 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding…

KRYS +0.2% todayRead at source ↗
● Defense WorldSep 17, 2026 · 03:32 ETEARNINGS EXPECTED BY FEB 16
Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS

Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commiss…

KRYS +0.2% todayRead at source ↗
● Defense WorldSep 11, 2026 · 03:39 ETEARNINGS EXPECTED BY FEB 16
Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS

Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased…

KRYS +0.2% todayRead at source ↗
● Zacks Investment ResearchSep 3, 2026 · 12:50 ET
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.…

KRYS +0.2% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026,…

KRYS +0.2% todayRead at source ↗
● Zacks Investment ResearchSep 2, 2026 · 12:31 ETEARNINGS EXPECTED BY FEB 16
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?…

KRYS +0.2% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just KRYS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.